Sonnet BioTherapeutics (SONN) Competitors $1.56 -0.03 (-1.89%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SONN vs. BNOX, RNAZ, VRAX, ALZN, ALBT, ORGS, LIXT, ADTX, FRTX, and CELZShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Bionomics (BNOX), TransCode Therapeutics (RNAZ), Virax Biolabs Group (VRAX), Alzamend Neuro (ALZN), Avalon GloboCare (ALBT), Orgenesis (ORGS), Lixte Biotechnology (LIXT), Aditxt (ADTX), Fresh Tracks Therapeutics (FRTX), and Creative Medical Technology (CELZ). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Bionomics TransCode Therapeutics Virax Biolabs Group Alzamend Neuro Avalon GloboCare Orgenesis Lixte Biotechnology Aditxt Fresh Tracks Therapeutics Creative Medical Technology Bionomics (NASDAQ:BNOX) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends. Do institutionals and insiders hold more shares of BNOX or SONN? 15.9% of Bionomics shares are owned by institutional investors. Comparatively, 9.4% of Sonnet BioTherapeutics shares are owned by institutional investors. 0.7% of Bionomics shares are owned by insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is BNOX or SONN more profitable? Bionomics' return on equity of 0.00% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets BionomicsN/A N/A N/A Sonnet BioTherapeutics N/A -398.45%-142.16% Do analysts rate BNOX or SONN? Bionomics presently has a consensus price target of $8.00, indicating a potential upside of 3,193.54%. Sonnet BioTherapeutics has a consensus price target of $20.00, indicating a potential upside of 1,182.05%. Given Bionomics' higher possible upside, equities research analysts plainly believe Bionomics is more favorable than Sonnet BioTherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bionomics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, BNOX or SONN? Bionomics has higher earnings, but lower revenue than Sonnet BioTherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBionomics$10K428.82-$15.49MN/AN/ASonnet BioTherapeutics$18.63K150.34-$18.83MN/AN/A Does the MarketBeat Community believe in BNOX or SONN? Bionomics and Sonnet BioTherapeutics both received 20 outperform votes by MarketBeat users. However, 83.33% of users gave Sonnet BioTherapeutics an outperform vote while only 76.92% of users gave Bionomics an outperform vote. CompanyUnderperformOutperformBionomicsOutperform Votes2076.92% Underperform Votes623.08% Sonnet BioTherapeuticsOutperform Votes2083.33% Underperform Votes416.67% Which has more risk and volatility, BNOX or SONN? Bionomics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Does the media favor BNOX or SONN? In the previous week, Sonnet BioTherapeutics had 3 more articles in the media than Bionomics. MarketBeat recorded 7 mentions for Sonnet BioTherapeutics and 4 mentions for Bionomics. Bionomics' average media sentiment score of 0.57 beat Sonnet BioTherapeutics' score of 0.05 indicating that Bionomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bionomics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sonnet BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBionomics beats Sonnet BioTherapeutics on 8 of the 13 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.80M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.1317.19Price / Sales150.34196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book-1.515.094.784.78Net Income-$18.83M$151.83M$120.31M$225.60M7 Day Performance-13.81%-2.14%-1.92%-1.23%1 Month Performance-47.65%-4.56%13.65%0.46%1 Year Performance-12.85%8.87%28.34%15.24% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics1.2757 of 5 stars$1.56-1.9%$20.00+1,182.1%-16.1%$2.80M$18,626.000.0012Analyst ForecastBNOXBionomics2.517 of 5 stars$0.29-11.8%$8.00+2,706.0%-81.3%$5.03M$10,000.000.00N/ARNAZTransCode Therapeutics2.9597 of 5 stars$7.13-3.9%$99.00+1,288.5%-99.9%$4.99MN/A0.009Analyst ForecastAnalyst RevisionNews CoveragePositive NewsVRAXVirax Biolabs Group0.6841 of 5 stars$1.52-3.2%N/A+25.0%$4.91M$84,872.000.005News CoverageALZNAlzamend Neuro2.6259 of 5 stars$1.26+5.9%$32.00+2,439.5%-87.7%$4.90MN/A0.004News CoveragePositive NewsALBTAvalon GloboCare0.3359 of 5 stars$4.34-5.7%N/A-55.4%$4.75M$1.31M-0.215ORGSOrgenesisN/A$0.98-3.9%N/AN/A$4.70M$530,000.000.00150News CoverageLIXTLixte BiotechnologyN/A$2.01+1.3%N/A-10.4%$4.52MN/A-1.153Positive NewsGap UpADTXAditxt0.6214 of 5 stars$0.32-9.5%N/A-99.9%$4.48M$640,000.000.0047FRTXFresh Tracks TherapeuticsN/A$0.75flatN/A-9.8%$4.48M$10.06M-0.5320CELZCreative Medical Technology0.5925 of 5 stars$2.34+6.8%N/A-55.2%$4.10M$10,000.00-0.615Positive News Related Companies and Tools Related Companies Bionomics Competitors TransCode Therapeutics Competitors Virax Biolabs Group Competitors Alzamend Neuro Competitors Avalon GloboCare Competitors Orgenesis Competitors Lixte Biotechnology Competitors Aditxt Competitors Fresh Tracks Therapeutics Competitors Creative Medical Technology Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SONN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SONN Stock Alerts